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S U M M A R Y
Schistosomiasis is a chronic enteropathogenic disease caused by blood ﬂukes of the genus
Schistosoma. The disease afﬂicts approximately 240 million individuals globally, causing approximately
70 million disability-adjusted life years lost. Chronic infections with morbidity and mortality occur as a
result of granuloma formation in the intestine, liver, or in the case of Schistosoma haematobium, the
bladder. Various methods are utilized to diagnose and evaluate liver ﬁbrosis due to schistosomiasis. Liver
biopsy is still considered the gold standard, but it is invasive. Diagnostic imaging has proven to be an
invaluable method in assessing hepatic morbidity in the hospital setting, but has practical limitations in
the ﬁeld. The potential of non-invasive biological markers, serum antibodies, cytokines, and circulating
host microRNAs to diagnose hepatic ﬁbrosis is presently undergoing evaluation. This review provides an
update on the recent advances made with respect to gastrointestinal disease associated with chronic
schistosomiasis.
 2014 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/3.0/).
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Schistosomiasis (bilharzia) is a chronic enteropathogenic
disease caused by blood ﬂukes of the genus Schistosoma.1 It affects
approximately 240 million people and is considered the third most
devastating tropical disease in Africa, South America, the
Caribbean, the Middle East, and Asia.2–4 More than 78 countries
are affected, and nearly 800 million people are at risk of
infection.3,4 Of the ﬁve species that infect humans, Schistosoma
mansoni, Schistosoma haematobium, and Schistosoma japonicum
cause the most morbidity.3,5 The disease burden due to these three
species is estimated to be as high as 29 million disability-adjusted
life years (DALYs).6
The lifecycles of the ﬁve schistosome species are similar and
involve a snail intermediate host (Figure 1). Chronic infections* Corresponding author.
E-mail address: a.ross@grifﬁth.edu.au (Allen G.P. Ross).
http://dx.doi.org/10.1016/j.ijid.2014.07.009
1201-9712/ 2014 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).with all Schistosoma species, with the exception of S. haematobium,
can cause signiﬁcant morbidity and mortality as a result of
granuloma formation in the intestine and liver.7 However, cases of
liver8 and intestinal disease9 from S. haematobium have also been
reported. This review emphasizes the pathogenesis of the
intestinal and hepatosplenic forms of the disease – the major
causes of morbidity in schistosomiasis mansoni and japonica. The
evaluation of hepatic ﬁbrosis with diagnostic imaging and the
performance of different direct serum biomarkers and potential
use of circulating microRNAs (miRNAs) for disease staging and
predicting the risk of hepatic ﬁbrosis are also discussed.
2. Chronic schistosomiasis
2.1. Intestinal disease
One of the common manifestations of the chronic form of this
enteropathogenic disease is intestinal schistosomiasis. The infec-
tion is caused by S. mansoni, S. japonicum, S. mekongi, and S.ciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
Figure 1. Schistosome lifecycle (Ross AG, McManus DP, Farrar J, Hunstman RJ, Gray
DJ, Li YS, et al. Neuroschistosomiasis. J Neurol 2012; 259:22–32).
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infection have also been reported.11,12 The pathology associated
with intestinal schistosomiasis is due to egg deposition and
granuloma formation, which eventually leads to acute then
chronic schistosomal colitis and polyp formation.13 Although
areas in both the small and large intestine may be involved, most
severe lesions are found in the large intestine. It is theorized that
the adult worms have a tendency to inhabit the branches of the
inferior mesenteric vein and superior hemorrhoidal vein; hence,
more eggs are deposited in the large intestine, especially in the
rectum, sigmoid, and descending colon.14
Ova are generally distributed in the loose submucosa of the large
intestine and to a lesser extent in the subserosa. The muscularis
mucosa subsequently becomes involved, and the underlying
mucosa may either undergo hyperplastic changes or be denuded
and form small superﬁcial ulcers. When the submucosa becomes
heavily thickened with ﬁbrous tissue containing massive amountsof calciﬁed eggs, atrophy of the overlying mucosa ensues and it
acquires a granular dirty yellowish appearance.15 Polyps, which are
said to be the most common among the spectrum of intestinal
lesions,16 may result from an immune-mediated inﬂammatory
process associated with continued egg deposition17 and ova
entrapment leading to a foreign body reaction with progressive
inﬂammation and ﬁbrosis. Schistosomal eggs are deposited in the
superﬁcial layers of the submucosa where reactive cellular debris
and vascular granulation tissue accumulate. Eggs will then produce a
cell-mediated inﬂammatory response with granuloma formation
and necrosis. The subsequent healing of the necrotic foci will lead to
the formation of ﬁbrous connective tissue and hypertrophy of the
muscularis mucosa. The ﬁbrous connective tissue in the submucosa
and the hypertrophied muscularis mucosa form a barrier to the ova
transiting from the mesenteric veins to the gut lumen. The trapped
ova then elicit further inﬂammation and ﬁbrosis. This continuous
process elevates the hypertrophied muscularis mucosa to form a
nodule which is the earliest detectable polyp.18
Clinical manifestations of intestinal schistosomiasis include
abdominal pain, altered bowel habits, and bloody stools.5 Iron-
deﬁciency anemia and eosinophilia are also present.19 Polyposis
from intestinal schistosomiasis does not appear to be related with
colorectal carcinoma,20,21 but a recent study has shown that a
history of colonic schistosomiasis japonica is a probable indepen-
dent risk factor for the development of colorectal neoplasias.22
Appendiceal schistosomiasis was ﬁrst documented in 1909, and
the most frequent species associated with this condition are S.
haematobium and S. mansoni. In one case report, schistosomiasis
haematobia presented as acute appendicitis in a 26-year-old Israeli
male who developed symptoms 2 years after visiting Africa; tissue
sections showed extensive inﬂammatory areas and ﬁbrosed
granulomas.9 This rare condition was also reported recently in a
30-year-old male UK resident from Ghana; histological sections of
his appendix revealed luminal pus associated with numerous S.
mansoni egg masses transmurally and within the subserosal
adipose tissue. The usual granulomatous response around the eggs
was evident. Eggs in the submucosa produce an obstructive type of
appendicitis, while serosal lesions produce inﬂammation and
adhesion formation.23
In Saudi Arabia, an unusual case of disseminated peritoneal S.
japonicum has also been reported in a 32-year-old Filipino female
who presented with signs and symptoms of acute appendicitis.
However, a right iliac fossa mass was also seen on diagnostic
laparoscopy. Microscopic sections of both the appendiceal wall and
the adherent omental mass showed suppurative inﬂammation and
multiple foci of schistosomal ova highly indicative of the S.
japonicum species. Interestingly, a granulomatous response was
not seen in the sections examined.24
2.2. Hepatosplenic disease
Hepatic schistosomiasis represents the best known form of
chronic disease with a wide range of clinical manifestations, and its
pathogenesis is related to the host cellular immune response.13
The mechanisms involved in granuloma formation and ﬁbrosis
have been documented extensively in experimental models and
humans infected with S. mansoni and S. japonicum. Eggs trapped in
the pre-sinusoidal portal venules secrete soluble egg antigens
which are taken up by antigen-presenting cells such as macro-
phages.25 Subsequently, antigen presentation stimulates Th1 cells
(CD4+ T lymphocytes) to secrete interleukin (IL)-2, interferon
gamma (IFN-g), and tumor necrosis factors (TNF), which in turn
drive a cell-mediated response and attract more immune cells
around the ova. As the granuloma becomes more organized, the
Th1 cells are gradually replaced by Th2 cells, which produce IL-4,
IL-5, IL-10, and IL-13, completing granuloma maturation.26
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stimulated by egg products and by T lymphocyte cytokines to
proliferate, replacing most of the cellular elements, and mediating
ﬁbrotic collagenous material deposition around the portal vein
tributaries. The pathogenesis of hepatic ﬁbrosis leading to
hepatosplenic schistosomiasis is illustrated for S. japonicum in
Figure 2.
Fibrosis, leading to portal hypertension, is the major cause of
disease morbidity and mortality. Grossly, whitish plaques known
as ‘clay-pipestem’ ﬁbrosis are evident on cut sections, contrasting
with the intact liver acinar architecture.27 Lesions commence as
eosinophilic inﬁltrates surrounding trapped eggs, which may
subsequently lead to abscess formation. A Splendore–Hoeppli
reaction (asteroid body formation) may sometimes occur.28 Peri-
ovular granulomas develop and the eggs inside degenerate and
calcify over time. As older granulomas involute, macrophage-
predominant granulomas begin to form.27 Eventually, granulomas
are replaced by surrounding ﬁbrous tissue. As more new eggs
arrive, resultant damage to larger diameter veins occurs, along
with periportal granulomatous inﬂammation and inter-granulo-
matous ﬁbrosis. In the absence of a coexisting hepatotropic viral
infection, the liver of patients with periportal ﬁbrosis secondary to
schistosomiasis retains its hepatocellular function, differentiating
the disease from cirrhosis and other liver diseases.7,29 Severe
schistosome-induced hepatic ﬁbrosis causes portal vein oblitera-
tion leading to the development of portal hypertension, and lethal
complications of the hepatosplenic form of the disease include
pulmonary hypertension,30,31 glomerulopathy,32,33 splenomegaly,
and thrombocytopenia.34Figure 2. Pathogenesis of hepatic ﬁbrosis leDespite the general mechanism of granuloma formation leading
to hepatic ﬁbrosis in schistosomiasis, studies have shown some
peculiarities regarding this pathogenesis among schistosome
species. For instance, in a study involving mouse models, tissue
studies were done to shed light on the characteristics of
granulomas caused by S. mekongi compared with S. japonicum-
induced granulomas. In the murine livers, it was shown that S.
mekongi-induced granulomas were initially cellular, formed by
foam cells, and continuously appeared in the intralobular areas,
while S. japonicum-induced granulomas were ﬁbrous and did not
continuously appeared in the intralobular areas. Portal ﬁbrosis was
also not observed in S. mekongi-infected murine livers, while this
lesion appeared later in livers infected with S. japonicum. It was
thought that the absence of portal ﬁbrosis in S. mekongi infection
allowed the eggs to inﬁltrate the interlobular areas continuously,
which may have accounted for the absence of echogenic pattern on
ultrasonographic evaluation (a feature noted with S. japonicum
species).35 On the other hand, in another study, the intensity of
liver ﬁbrosis among patients with S. mekongi infection was
assessed by liver biopsy. Liver biopsies revealed complete
disorganization of hepatic architecture with ﬁbrous enlargement
of portal tracts and some portal–portal bridging ﬁbrosis, but there
was no cirrhosis. There was blood vessel congestion and
thrombosis with inﬂammation in the portal areas. Numerous eggs
of S. mekongi were observed mostly in ﬁbrous areas and more
rarely in the parenchyma. Some eggs were surrounded by
epithelioid and giant cell reaction. A high degree of ﬁbrosis was
observed among young adults in that study and this contrasts with
the ﬁndings observed with other schistosome species.36ading to hepatosplenic schistosomiasis.
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S. mansoni and S. japonicum infections.37 Clinical hepatomegaly,
splenomegaly, reported blood in stool,38,39 abdominal pain,38
diverted circulation, and ascites39 are the frequent reported
clinical signs in studies assessing hepatosplenic morbidity from
S. mekongi.
Although several studies have clearly shown that schistosome
egg-induced granulomas are pathogenic to the host, there are
some current studies suggesting that the lesions may have some
protective functions. In an S. mansoni study40 involving
transgenic mice, it was thought that granuloma formation
around the egg offered some protection against schistosome-
related hepatotoxicity (an occurrence that is currently observed
only in S. mansoni-infected mice). Mice that were not able to
produce the necessary cytokines to form a functional granuloma
died early due to egg-induced endotoxemia. The granuloma
is not only thought to act as a physical barrier, but also functions
to sequester the antigenic products secreted by the egg.
Nevertheless, it is also thought that the parasite takes advantage
of this functional granuloma by facilitating excretion of its
eggs, without killing the host, and therefore continuing its
lifecycle.41
Recently, hepatic stellate cells (HSCs) have been acknowl-
edged to be major players in the liver ﬁbrotic process.42 The
interactions of the HSCs with S. japonicum43 and S. mansoni
eggs44 have been investigated; both studies supported the
contributory role of these cells in schistosome-induced hepatic
ﬁbrosis. Further, it has been demonstrated that the activated HSC
myoﬁbroblastic phenotype can be reversed to its quiescent
phenotype (manifested by lipoprotein storage in cells) by S.
mansoni egg antigens, an interaction not observed with
S. japonicum eggs. This inability of the S. japonicum eggs to
induce a quiescent myoﬁbroblastic phenotype has been sug-
gested to explain in part why S. japonicum is more pathogenic to
the liver compared with S. mansoni.45
3. Evaluation of hepatic ﬁbrosis
The pathology of schistosome-induced liver disease has been
studied extensively since its ﬁrst description in 1904.46 The term
‘Symmers ﬁbrosis’ was originally adopted to describe the unusual
pattern of collagen and glycosaminoglycan (GAG) deposition
observed in an autopsy. This term was changed in 1947 to clay-
pipestem ﬁbrosis in recognition of the fact that the hepatic
parenchyma was spared in schistosomal-induced liver disease and
appeared fundamentally different from ‘cirrhotic’ deposits of
collagen and GAGs.47
Currently there are a number of methods that can be used to
diagnose and evaluate the severity of liver ﬁbrosis. Liver biopsy
is considered the gold standard but causes signiﬁcant discomfort
and possible post-procedural risk. The evaluation of tissue
morphology may be informative but does not have sufﬁcient
sensitivity to diagnose periportal ﬁbrosis (PPF) and cannot
explain the disease dynamics occurring between sampling
periods.48 Imaging modalities like ultrasound (US), computed
tomography (CT), and magnetic resonance imaging (MRI), on the
other hand, are used not only to support the diagnosis of
schistosomiasis but also to accurately assess and detect target
organ damage that can develop due to chronic infection with
schistosomiasis. Research to identify non-invasive markers for
hepatic ﬁbrosis is also underway and the combination of these
biomarkers along with comprehensive history and physical
examination, basic laboratory tests, and imaging methods seems
to offer the best approach for evaluating patients with this
disease.493.1. Diagnostic imaging
The reliability of US has made it the routine imaging method in
the evaluation of hepatosplenic schistosomiasis for the past
30 years.50–53 In the diagnosis of S. mansoni, US can demonstrate
PPF appearing as echogenic tubular shadows with an anechoic
lumen that radiates from the porta hepatis. When the tubular
structure is viewed crosswise, it appears as a ring of concentric
ﬁbrosis surrounding portal venous vasculature, and is known as the
‘bull’s eye lesion’.54–56 Other US ﬁndings include hypertrophy of the
left hepatic lobe, atrophy of the right hepatic lobe, gallbladder wall
thickening, granulomas, and splenic nodules. The above lesions can
also be seen in liver pathology associated with S. japonicum infection.
However, the demonstration of a septal formation by high echogenic
bands like a mosaic or network pattern in the liver by US is typical
only for S. japonicum infection.57,58
CT, on the other hand, is not routinely used in the evaluation of
schistosomiasis due to its cost and the utilization of ionizing
radiation. CT scans show similar imaging ﬁndings to US, including
atrophy of the right hepatic lobe, hypertrophy of the left hepatic
lobe, splenomegaly, and ascites. PPF is seen in CT as a band of low
attenuation around portal vein branches throughout the liver, with
enhancement following the intravenous administration of contrast
medium. The ‘bull’s eye’ lesion in the liver can be demonstrated on
CT as concentric layers of periportal enhancement and is thought
by some authors to be a more speciﬁc indicator of schistosomiasis
than the periportal enhancement.59 The network pattern seen in
the liver in S. japonica appears on CT as a ‘turtleback’ or
‘tortoiseshell’ lesion. This lesion is thought to be due to septal
calciﬁcation of schistosomal ova.60
In the diagnosis of hepatosplenic schistosomiasis using MRI, the
most frequent ﬁndings are accentuation of periportal signal in T2-
weighted sequences, and a hypointense signal in relation to the
normal liver parenchyma in T1-weighted sequences with fat
suppression. The periportal signal is accentuated on T1-weighted
sequences following contrast administration. It has been suggested
that periportal inﬂammation may be differentiated from ﬁbrosis
by the hyperintense signal observed in T2-weighted sequences.61
Portal vein thrombosis (PVT), which may be due to hepatosplenic
schistosomiasis, is best diagnosed by MRI.62 Cavernous portal vein
transformation due to PVT is described on MRI as small enhancing
ﬂow voids around the right portal vein in a T1-weighted image.
Although MRI uses a gadolinium-based contrast, its higher cost
precludes routine use.
The utility of imaging techniques in the diagnosis of schistoso-
miasis is demonstrated in Figure 3. A 12-year-old Filipino boy from
a known schistosomiasis endemic area in the central Philippines
was diagnosed by portable gray-scale US to have moderate PPF
with severe splenomegaly due to schistosomiasis japonica. Further
examination with MRI conﬁrmed the PPF and showed an
additional ﬁnding of PVT and cavernous transformation of the
right branch of the main portal vein. Massive splenomegaly was
also demonstrated on MRI. The patient was successfully treated by
splenectomy.
3.2. Serum biological markers
The supporting framework of the normal and ﬁbrotic liver
comprises a group of macromolecules called extracellular matrix
(ECM). In advanced stages of ﬁbrosis, the liver contains approxi-
mately six times more ECM than normal, including collagens (I, III,
and IV), ﬁbronectin, undulin, elastin, laminin, hyaluronan, and
proteoglycan.63 Qualitative and quantitative ECM changes in liver
ﬁbrosis can be measured in the blood or urine using indirect and
direct biomarkers. Direct biomarkers are classiﬁed into three
groups: (1) those that measure matrix deposition: procollagen I
Figure 3. The abdomen of a 12-year-boy with severe schistosomiasis (A) before and (B) after splenectomy. Ultrasound of the patient showing (C) a markedly thickened branch
of the main portal vein (white arrow), and (D) a markedly enlarged spleen with dilated splenic vein (black arrow). MRI depicting (E) a cavernous transformation of the right
portal vein (black arrow) and periportal ﬁbrosis running along the second branch of the portal vein (white arrow), and (F) curvilinear tracts scattered throughout the liver
parenchyma consistent with periportal ﬁbrosis (arrows). Histopathology sections showing (G) early Schistosoma japonicum egg granuloma and (H) late granuloma in the liver.
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peptide (PIIINP), tissue inhibitors of metalloproteinase (TIMPs),
transforming growth factor beta (TGF-b), tenascin; (2) those that
reﬂect matrix removal or degradation: procollagen IV C peptide,
procollagen IV N peptide (7-S collagen), collagen IV, metallopro-
teinase MMP, undulin, urinary desmosine, and hydroxylysylpyr-
idinoline; and (3) those that cannot clearly determine the
relationship to the matrix deposition or removal: hyaluronic acid,
YKL-40 (Chondrex), and laminin.63,64 Many of these biomarkers
have been evaluated and found useful in the diagnosis and grading
of liver ﬁbrosis caused by several conditions, including chronic
viral hepatitis, alcoholic cirrhosis, non-alcoholic steatohepatitis,
and schistosomiasis.65 However, their ability to identify and grade
liver ﬁbrosis in schistosomiasis at the community level in endemic
areas needs further evaluation. The performance of some direct
serum markers in the evaluation of schistosome-induced hepatic
ﬁbrosis is discussed below and is summarized in Table 1.
3.3. Collagen
Collagen and its metabolic products have been examined in the
blood and urine of patients with different etiologies of ﬁbrotic liver
disease.66 Collagen types I, III, and IV have been used extensively in
the evaluation of hepatic ﬁbrosis. Serum PIIINP has also gained
wide acceptance as a blood test for collagen metabolism.67 Type III
collagen is secreted in the extracellular space as a procollagen
molecule. The amino terminal portion of the molecule is then
cleared by enzymatic cleavage by two speciﬁc endopeptidases.68
This releases the helical type III collagen molecule to combine with
other ECM macromolecules to form a collagen ﬁbril. This short
peptide fragment (PIIIP) diffuses from ﬁbrotic loci, circulates in the
blood, and is metabolized further to form a fragment termed Col-1
(procollagen type I peptide (PIP)).69 The PIIIP assay appears to haveits greatest utility in the early stages of ﬁbrosis when type III
collagen biosynthesis predominates.70 In the late stages of most
cirrhotic conditions, PIP is the dominant peptide synthesized.71 A
study on PICP in schistosomiasis mansoni showed that the levels of
this biomarker were higher in infected patients than in uninfected
controls and that serum levels decreased during the ﬁrst year post-
treatment with the anti-schistosome drug praziquantel; however,
no correlation was established between PIP and ﬁbrosis scores by
US examination.72 On the other hand, PIIINP levels in schistoso-
miasis mansoni were elevated in patients with hepatic disease
compared with normal or uncomplicated control subjects. In
another study it was shown that PIIINP levels returned to normal
levels 18 months after patients received praziquantel.71 Higher
levels of PIIINP were also observed in subjects with advanced PPF
diagnosed by histology or with more severe hepatic disease.73
Serum type IV collagen has also been examined in schistoso-
miasis patients. Levels of procollagen IV peptide did not correlate
with the presence or intensity of infection, but they correlated
signiﬁcantly with liver ﬁbrosis, splenomegaly, portal vein dilata-
tion, and the presence of portosystemic collaterals.74,75 In another
study, a positive correlation between type IV collagen and
advanced schistosomiasis was noted, with a signiﬁcant reduction
being observed in serum levels following splenectomy, but there
was no correlation with the grade of PPF as determined by US.76,77
3.4. Hyaluronic acid
Hyaluronic acid (HA), a high molecular weight GAG, is an
essential ECM component. It is synthesized by HSCs and is
degraded by the sinusoidal endothelial cells.78,79 Increased levels
are due either to decreased hepatic removal or to increased
production by stellate cells, or to both processes.80 Several studies
have examined HA serum levels in a number of chronic liver
Table 1
Performance of serum markers in the evaluation of hepatic ﬁbrosis due to schistosomiasis
Serum marker Species Studies undertaken Results Reference
HA S. mansoni Correlation of levels of HA in patients with
intense, moderate, light, and without
ﬁbrosis by US in 79 subjects
HA was able to separate individuals with
ﬁbrosis from those without, and light from
intense ﬁbrosis. The HA diagnostic accuracy
for ﬁbrosis was 0.89. With a cut-off level of
115.4 ng/ml, sensitivity and speciﬁcity
were 0.98 and 0.64, respectively
Marinho et al., 2010
(Brazil)64
A study of 61 patients with schistosomiasis
mansoni and 16 healthy individuals
A serum HA level of 20.2 mg/l was observed
that differentiated between patients with
milder PPF (patterns C + D) and those with
more severe PPF by US, with a sensitivity of
60% and a speciﬁcity of 65%
Silva et al., 2011 (Brazil)87
Correlation of HA level in hepatosplenic
schistosomiasis and with mild to advanced
ﬁbrosis
Higher levels of HA were noted in more
advanced forms of schistosomiasis
Ricard-Blum et al., 1999
(Madagascar)72
Serum levels in advanced forms of the
disease
Serum HA levels were increased Pascal et al., 200085, and
Eboumbou et al., 2005
(Sudan)126
Levels of HA in 153 patients in Senegal with
schistosomiasis hepatic ﬁbrosis
No changes in patient levels of HA. However
60% of patients showed early stages of
hepatic involvement with US, while only 3%
presented with HS disease
Burchard et al., 1998
(Senegal)100
S. japonicum HA levels in 38 cases with portal
hypertension
Levels of HA are higher in those with portal
hypertension than the normal range
Guangjin et al., 2002
(China)127
HA levels in 193 individuals exposed to
endemic Schistosoma japonicum
HA levels correlated with US ﬁndings Li, Sleigh et al., 2000
(China)128
Patients were identiﬁed with either mild
(n = 30) or severe (n = 30) hepatic ﬁbrosis
due to S. japonicum infection
HA levels in normal, mild, and severe cases
of hepatic ﬁbrosis were 83.0  35.7,
216.1  77.9, and 212.6  80.9 mg/ml,
respectively. HA levels did correlate well
with the degree of ﬁbrosis.
Zheng et al., 2005 (China)92
TIMPs S. japonicum 611 S. japonicum-infected Filipinos were
treated with praziquantel; FibroPlex
analytes produced by peripheral blood
mononuclear cells stimulated with
schistosome egg antigen 4 weeks after
praziquantel treatment were measured and
these levels related to the risk of ﬁbrosis
1 year after praziquantel treatment
Individuals with detectable TIMP-1 had a
3.5-fold greater risk of ﬁbrosis 1 year after
praziquantel treatment compared to
individuals with undetectable levels (OR
3.48; 95% CI 1.41–8.43; P = 0.007)
Fabre et al., 2011
(Philippines)99
Laminin S. mansoni Correlation of levels with portal
hypertension
Laminin levels correlated with portal
hypertension
Ricard-Blum et al., 1999
(Madagascar)72
Field studies evaluating the levels of
laminin in individuals with milder forms of
schistosomiasis
Results did not reveal a correlation between
laminin levels and milder forms of PPF
Kardorff et al., 1997, 1999
(Tanzania)74,75
Correlation of serum laminin levels with
infection (egg-positive infected patients)
Serum laminin level was signiﬁcantly
higher in egg-positive infected patients
than in endemic controls
Tanabe et al., 1989
(Brazil)101; Ricard-Blum
et al., 1999 (Madagascar)72
Serum levels of laminin in hepatosplenic
and hepatointestinal patients
Serum levels of laminin were higher in
hepatosplenic than in hepatointestinal
patients and were also higher in
hepatointestinal patients than the controls
Parise and Rosa, 1992
(Brazil)76
Laminin levels were determined in cases
with initial stages of disease in
hepatointestinal cases and in advanced
disease
Progressive increase of laminin levels in
those with initial to advanced cases of
hepatointestinal schistosomiasis were
observed
Wyszomirska et al., 2005
(Brazil)76
S. japonicum Laminin levels in 193 individuals exposed
to endemic S. japonicum
Levels of laminin are correlated with re-
infection
Sleigh et al., 2000
(China)128
Collagen IV S. mansoni Correlation of procollagen IV peptide levels
and intensity of schistosomiasis, liver
ﬁbrosis, splenomegaly, portal vein
dilatation, and the presence of
portosystemic collaterals
Levels of procollagen IV peptide did not
correlate with the presence or intensity of
schistosomiasis infection, but were
signiﬁcantly correlated with liver ﬁbrosis
and signs of portal hypertension. Type IV
collagen had a good speciﬁcity (over 90%)
but poor sensitivity because more than half
of those with severe liver involvement
exhibited normal levels of type IV collagen
Kardorff et al., 1997, 1999
(Tanzania)74,75
Correlation between type IV collagen and
advanced forms of schistosomiasis mansoni
A positive correlation between type IV
collagen and advanced forms of
schistosomiasis mansoni. However, no
correlation to the grade of PPF assessed by
US examination as the gold standard
method
Wyszomirska et al., 2005,
2006 (Brazil)76
S. japonicum Collagen IV levels in 193 individuals
exposed to endemic S. japonicum
Levels of collagen IV correlated with re-
infection
Sleigh et al., 2000
(China)128
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Table 1 (Continued )
Serum marker Species Studies undertaken Results Reference
Procollagen type III S. mansoni Levels of PIIIP in 82 individuals infected
with S. mansoni without liver enlargement
and 20 with hepatic or hepatosplenic
disease
PIIINP was elevated in patients with hepatic
disease, but normal in uncomplicated cases
Zwingenberger et al., 1988
(Zaire)71
Correlation of levels of PIIIP with the
presence or intensity of infection or ﬁbrosis
scores
No signiﬁcant correlation evident between
PIIIP levels and the presence or intensity of
infection or ﬁbrosis scores
Kardorff et al., 1997, 1999
(Tanzania)74,75; Tanabe
et al., 1989 (Brazil)101;
Burchard et al., 1998
(Senegal)100; Ricard-Blum
et al., 1999 (Madagascar)72
S. japonicum PIIIP levels in 38 cases with portal
hypertension.
Levels of PIIIP were higher in those with
portal hypertension than the normal range
Guangjin et al., 2002
(China)127
YKL-40 S. japonicum Levels of YKL-40 were determined in
60 patients with mild, moderate, or severe
hepatic ﬁbrosis due to S. japonicum
infection
Levels of YKL-40 were 49.0  10.4,
92.3  18.5, and 172.1  35.9 mg/ml,
respectively for mild, moderate, and severe
hepatic ﬁbrosis. Serum levels of YKL-40
correlated with the stage of hepatic ﬁbrosis
Zheng et al., 2005 (China)92
HA, hyaluronic acid; US, ultrasound; PPF, periportal ﬁbrosis; HS, hepatosplenic; TIMP, tissue inhibitor of metalloproteinase; OR, odds ratio; CI, conﬁdence interval; PIIIP,
aminoterminal procollagen III-peptide; PIIINP, procollagen III amino terminal peptide.
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detecting ﬁbrosis in cirrhosis, chronic hepatitis B and C, and
alcoholic and non-alcoholic fatty liver disease.79,81–84 Studies in
patients with different degrees of ﬁbrosis due to schistosomiasis
mansoni have suggested a correlation between HA serum levels
and disease severity. More severe cases of PPF had much higher
levels of HA, while subjects with mild ﬁbrosis had low HA
levels.85–87 The evaluation of serum levels of HA and type IV
collagen with respect to US patterns of PPF showed that only the
former was capable of separating patients with mild ﬁbrosis from
those with intense ﬁbrosis. Moreover, HA correlated positively
with portal hypertension and PPF, and collateral circulation
predicted HA increase.64 It is also noteworthy that, as with serum
type I collagen, the high HA levels in patients with hepatic ﬁbrosis
were reduced following praziquantel treatment.72 In another study
involving advanced schistosomiasis japonica patients and controls,
serum HA and TIMP-1 levels were elevated in the former, with HA
outperforming TIMP-1.48
3.5. Chitinase-3-like protein 1
Chitinase-3-like protein 1 (YKL-40) is a novel liver ﬁbrosis
marker. This recently described glycoprotein belongs to the
chitinase family and is expressed in human liver and arthritic
articular cartilage.89–91 Although its precise physiological function
is not known, YKL-40 is thought to contribute to tissue remodeling
or degradation of the ECM in liver ﬁbrosis. In a study of patients
with hepatitis C virus (HCV)-associated liver disease comparing
type IV collagen, PIIINP, HA, YKL-40, and biochemical parameters
in the assessment of hepatic ﬁbrosis, it was concluded that HA and
YKL-40 were more useful than the other markers for assessing the
ﬁbrosis stage; in particular, YKL-40 was the most useful for
monitoring the ﬁbrosis of liver disease and for distinguishing
extensive from the mild stage of liver ﬁbrosis assessing the ﬁbrosis
stage.89Additionally,YKL-40 was more sensitive than HA in
measuring the degree of hepatic ﬁbrosis due to schistosomiasis;
the serum levels increased in patients infected with S. japonicum
and correlated with the hepatic ﬁbrosis stage.92
3.6. Matrix metalloproteinases and inhibitors
The matrix metalloproteinases (MMPs) and their inhibitors are
involved in controlling matrix degradation. MMPs are enzymes
that are produced intracellularly and secreted as proenzymes,
which require cleavage by cell surface mechanisms for functionalactivity. The action of MMPs is counteracted by TIMPs.93 As such,
they act to degrade ECM and to permit new matrix deposition. It
has been suggested that the imbalance between MMPs and TIMPs
affects the rate of ﬁbrosis progression and that their levels
correlate with the ﬁbrosis stage, but the results have been variable
and dependent upon the MMP/TIMP being assessed.94–96
The diagnostic accuracy of TIMP-1 and pro-MMP-2 (the free
precursor molecule of MMP-2) and their relationships to
histological inﬂammatory scores have been evaluated in patients
with HCV infection; both assays performed either as well as or
better than HA for the diagnosis of cirrhosis, but only TIMP-1
showed diagnostic value for the identiﬁcation of patients with
early stages of ﬁbrosis. The levels of MMP-2 exhibited no
relationship with the stage of ﬁbrosis, thereby limiting its value
for staging liver disease.95,97,98 Serum MMP-1 and MMP-3 levels
have also been shown not to have any diagnostic value.94,96 On the
other hand, one study has demonstrated that TIMP-1 can predict
the risk of hepatic ﬁbrosis in patients after 1 year of praziquantel
treatment. This highlights the importance of identifying biomark-
ers for ﬁbrosis risk because ﬁbrosis can occur despite effective
treatment.99
3.7. Laminin
Laminin is a major non-collagenous glycoprotein of basement
membranes. Synthesized by HSCs, serum levels of laminin
correlate with portal hypertension.72 Field studies evaluating
individuals with milder forms of schistosomiasis did not, however,
reveal a correlation between laminin and PPF or the presence or
intensity of infection.72,74,75,100 However, some studies noted that
the mean value of serum laminin was signiﬁcantly higher in egg-
positive schistosome-infected patients than in endemic con-
trols.72,101 In another study, serum laminin levels were shown
to be higher in hepatic schistosomiasis subjects than in hepa-
tointestinal patients and were also higher in the latter compared
with controls.102 A progressive increase in laminin has also been
reported in the initial stages of hepatointestinal schistosomiasis
and in advanced cases.76,103
3.8. Cytokines
Cytokines have been evaluated as biomarkers of hepatic
ﬁbrogenesis in a limited number of studies on schistosomiasis,
with conﬂicting results. TGF-b is the dominant stimulus for
producing ECM by HSCs. In a study of 88 patients who had chronic
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degree of hepatic ﬁbrosis.103 The role of cytokines in the
development of hepatic ﬁbrosis before the hepatosplenic and
early hepatosplenic stages of schistosomiasis mansoni was
evaluated in a group of patients with different degrees of hepatic
ﬁbrosis determined by US. Peripheral blood mononuclear cells
(PBMCs) from schistosomiasis japonica patients were stimulated
by S. japonicum antigens and the levels of IL-5, IL-10, IL-13, IFN-g,
TNF-a, and TGF-b determined in the PBMC supernatants. Of
signiﬁcance, higher levels of IL-5, IL-10, and IL-13 were found in
the supernatants of soluble egg antigen-stimulated PBMCs from
subjects with stage III hepatic ﬁbrosis compared to patients with
stage I or II ﬁbrosis. Signiﬁcant increases in IL-5 and IL-13 levels
were also observed in some of the subjects who remained
untreated for 1 year following initial assessment and who
developed more serious ﬁbrosis during this period.104 In a study
of hepatosplenic schistosomiasis mansoni, there was no signiﬁcant
difference in the mean serum concentrations of IL-10 and IL-13
between the different categories of hepatosplenic disease.105
3.9. Circulating miRNAs
miRNAs comprise a family of conserved small non-coding RNAs
(approximately 22 nucleotides) that can be detected in a wide
range of body ﬂuids, including blood plasma/serum. The high level
of stability of miRNAs in bioﬂuids has been attributed to two
mechanisms: (1) formation of a protein–miRNA complex with
argonaute proteins (mainly Ago2)106 or high-density lipopro-
teins,107 and (2) incorporation into exosomes,108 macrovesicles, or
apoptotic bodies.109 miRNAs are being developed as novel
biomarkers for various cancers and other diseases.110–112
For example, serum levels of liver-speciﬁc miR-122 and miR-
34a were suggested to be correlated with ﬁbrosis, steatosis, and
inﬂammatory activities in a study of chronic HCV infection and
non-alcoholic fatty liver disease (NAFLD).113 Liver ﬁbrosis and/or
cirrhosis were also shown to be associated with increased serum
levels of miR-571 and miR-513-3p and reduced serum levels of
miR-29 and miR-652.114 A recent study in HCV-infected patients
has suggested that serum miR-20a may serve as a predictive
biomarker for HCV-mediated ﬁbrosis.115 It is noteworthy that the
serum exosomal miRNA expression proﬁle was linked to grade and
stages of liver ﬁbrosis in patients with chronic HCV infection. The
expression levels of two miRNAs (miR-483-5p and miR-671-5p)
increased signiﬁcantly and the expression levels of 14 miRNAs (let-
7a, miR-106b, miR-1274a, miR-130b, miR-140-3p, miR-151-3p,
miR-181a, miR-19b, miR-21, miR-24, miR-375, miR-548l, miR-93,
and miR-941) were progressively reduced as liver ﬁbrosis
increased.116
As schistosomal egg-induced immunopathology is an unusual
type of chronic liver disease distinguishable from many other liver
disease types, it is tempting to speculate that a unique set of
circulating miRNAs may be deﬁned to potentially serve as sensitive
molecular signatures for assessment of the severity of the ﬁbrotic
pathology of schistosomiasis. To date, a set of miRNAs of parasite
origin have been identiﬁed in both S. japonicum117,118 and S.
mansoni 119,120 and miRNA expression proﬁles at different
developmental stages of S. japonicum have been character-
ized.121,122 However, the abundance of schistosome-speciﬁc
miRNAs in the plasma of the deﬁnitive mammalian host has been
shown to be relatively low, which will likely limit its utility for the
diagnosis and staging of schistosomiasis.123 Encouragingly, how-
ever, alterations of speciﬁc host miRNAs within different tissues
have been shown to be associated with S. japonicum infection. The
expression of several host miRNAs was shown to be altered rapidly
in the lungs, liver, and spleen of BALB/c mice as early as 10 days
post infection with S. japonicum.124 A broad array of miRNAs inliver was dysregulated and associated with the progression of S.
japonicum infection.125 These results raise the possibility that
circulating host miRNAs may be dynamically altered during the
course of schistosome infection; this provides an avenue for their
development as useful diagnostic and pathogenic biomarkers for
schistosomiasis, because of the strong correlation between the
expression proﬁle of miRNAs and the status/progression of the
disease.
4. Conclusions
Schistosomiasis can causes signiﬁcant pathology and chronic
morbidity in humans infected with numerous egg granulomas and
this typically results in ﬁbrosis in target organs. The intestinal form
of the disease is caused by the deposition of eggs within the bowel
wall, while the hepatosplenic form of the disease is due to the eggs
trapped in the liver pre-sinusoids. In the former, the eggs cause
bowel lesions ranging from colitis to polyp formation, whereas in
the latter, granuloma formation and subsequent ﬁbrosis involve
immune responses initially mediated by Th1 and later by Th2
lymphocytes. Severe ﬁbrosis leads to portal hypertension-related
complications causing signiﬁcant illness or death.
There are various methods to diagnose and evaluate schisto-
some-induced liver ﬁbrosis. Liver biopsy is still considered the gold
standard, but the procedure is clinically impractical in the ﬁeld.
Ultrasonography is invaluable in assessing pathology, but is not
readily available in many endemic communities, and the results
among users can vary widely. Although costly and limited to the
hospital setting, CT and MRI show distinct imaging features
associated with hepatosplenic schistosomiasis and aid in the
diagnosis and clinical management of patients.
Attention has recently been given to non-invasive biological
markers that can determine the severity of hepatic ﬁbrosis and
monitor qualitative and quantitative changes following treatment.
The most promising serum markers for the evaluation of
schistosome-induced hepatic ﬁbrosis appear to be hyaluronic
acid, collagen type III, YKL-40, and laminin. More studies are
needed to evaluate the utility of matrix metalloproteinases and
inhibitors, and cytokines. Circulating host miRNAs show promise
as useful biomarkers for schistosomiasis diagnosis due to the
strong correlation between the expression proﬁle of miRNAs and
the disease status/progression. Biological markers are presently
limited to research investigations and may prove too costly for
broader clinical application, but their potential role in the
diagnosis of schistosomiasis warrants further investigation.
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